Milne, Paul, Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158, Grunwald, Michael R., Bigley, Venetia, Dillon, Richard, Freeman, Sylvie D., Gallagher, Kathleen, Publicover, Amy, Pagan, Sarah, Marr, Helen, Jones, Gail L., Dickinson, Anne M., Grech, Angela, Burnett, Alan K., Russell, Nigel H., Levis, Mark, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441 and Collin, Matthew
2019.
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.
Blood Advances
3
(20)
, pp. 3052-3061.
10.1182/bloodadvances.2019000197
|
|
|
Ivey, Adam, Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Simpson, Michael A., Jovanovic, Jelena V., Gilkes, Amanda, Grech, Angela, Patel, Yashma, Bhudia, Neesa, Farah, Hassan, Mason, Joanne, Wall, Kerry, Akiki, Susanna, Griffiths, Michael, Solomon, Ellen, McCaughan, Frank, Linch, David C., Gale, Rosemary E., Vyas, Paresh, Freeman, Sylvie D., Russell, Nigel, Burnett, Alan K. and Grimwade, David
2016.
Assessment of minimal residual disease in standard-risk AML.
New England Journal of Medicine
374
(5)
, pp. 422-433.
10.1056/NEJMoa1507471
|
|
Burnett, Alan K., Russell, Nigel H., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Bowen, David, Kell, Jonathan, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Morgan, Yvonne G., Lok, Jennie, Grech, Angela, Jones, Gail, Khwaja, Asim, Friis, Lone, McMullin, Mary Frances, Hunter, Ann, Clark, Richard E. and Grimwade, David
2015.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncology
16
(13)
, pp. 1295-1305.
10.1016/S1470-2045(15)00193-X
|
|
Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062
2015.
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts.
British Journal of Haematology
170
(1)
, pp. 80-84.
10.1111/bjh.13398
|
|



Up a level